Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H17NO3 |
| Molecular Weight | 223.2683 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C(=O)C1=CC=C(O)C(OC)=C1
InChI
InChIKey=BQJODPIMMWWMFC-UHFFFAOYSA-N
InChI=1S/C12H17NO3/c1-4-13(5-2)12(15)9-6-7-10(14)11(8-9)16-3/h6-8,14H,4-5H2,1-3H3
| Molecular Formula | C12H17NO3 |
| Molecular Weight | 223.2683 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/4387399
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4387399
Ethamivan or etamivan, a respiratory stimulant was used in pulmonary emphysema.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
10000 mg multiple, intravenous Highest studied dose Dose: 10000 mg Route: intravenous Route: multiple Dose: 10000 mg Sources: |
unhealthy, 21 years |
|
500 mg single, oral Highest studied dose |
unhealthy |
|
2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (4 patients) Sources: Vomiting (1 patient) Muscle twitching (4 patients) Dysphoria (4 patients) Fatigue (4 patients) Dizziness (2 patients) Dyspnea (2 patients) Ear buzzing (1 patient) Vertigo (2 patients) Visual hallucinations (1 patient) Pruritus (1 patient) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Ear buzzing | 1 patient | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy |
| Pruritus | 1 patient | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy |
| Visual hallucinations | 1 patient | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy |
| Vomiting | 1 patient | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy |
| Dizziness | 2 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy |
| Dyspnea | 2 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy |
| Vertigo | 2 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy |
| Dysphoria | 4 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy |
| Fatigue | 4 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy |
| Muscle twitching | 4 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy |
| Nausea | 4 patients | 2.5 mg/kg single, intravenous Highest studied dose Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: |
unhealthy |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pentylenetetrazol and ethamivan effects on brain serotonin metabolism. | 1970-07-15 |
|
| Respiratory depression in the coma of myxedema: treatment with ethamivan intravenously. | 1969-10 |
|
| Effect of oral ethamivan on daily fluctuations of carbon dioxide tension in pulmonary emphysema with carbon dioxide retention. | 1969-01 |
|
| Effect of ethamivan on alveolar ventilation in patients with chronic lung disease. | 1962-12-20 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4387399
Unknown
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:33:30 GMT 2025
by
admin
on
Mon Mar 31 17:33:30 GMT 2025
|
| Record UNII |
M44O63YPV9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47795
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
||
|
WHO-ATC |
R07AB04
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
||
|
WHO-VATC |
QR07AB04
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1074
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
406087
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
DB08989
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
1174
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
Etamivan
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
24453
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID3023007
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
SUB07259MIG
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
92675
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
100000082368
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
304-84-7
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
C100268
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
206-157-3
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
M44O63YPV9
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
9363
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
CHEMBL1229908
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | |||
|
m5046
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY | Merck Index | ||
|
C76623
Created by
admin on Mon Mar 31 17:33:30 GMT 2025 , Edited by admin on Mon Mar 31 17:33:30 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |